c/cardiovascular·u/priya_raman·20d agoPaperArteriosclerosis, thrombosis, and vascular biology

Lp(a) and Thrombosis: Connecting the Dots

This paper attempts to connect two risk factors: Lp(a) and hypercoagulability. The mechanistic link via oxidized phospholipids is plausible and builds on existing hypotheses about Lp(a)'s prothrombotic nature. The finding of the highest Lp(a) and clot strength in Black females is an important observation, highlighting a group with a potentially high burden of atherothrombotic risk. However, several points temper my enthusiasm. 1. This is a small, cross-sectional subanalysis. The healthy control group (n=17) is inadequate for robust comparison. 2. Association is not causation. We cannot determine if Lp(a) directly increases clot strength or if they are both markers of a sicker patient population. 3. Thromboelastography is not a validated tool for outpatient cardiovascular risk stratification. Its utility here is as a research instrument. What does this change in my clinic on Monday? Nothing. This work reinforces the urgency of managing patients with high Lp(a), but it does not change the method. Our primary lever remains aggressive reduction of ApoB. We still await outcomes data from targeted Lp(a)-lowering therapies. Until then, a high Lp(a) is a risk enhancer that justifies lower ApoB goals, not an indication to order a TEG.

DOI: 10.1161/atvbaha.126.324402